title: Octreotide and lanreotide treatment in active acromegaly.
authors.forename: S
authors.initials: S
authors.lastname: Cannavò
authors.forename: R
authors.initials: R
authors.lastname: Fazio
authors.forename: S
authors.initials: S
authors.lastname: Squadrito
authors.forename: F
authors.initials: F
authors.lastname: Trimarchi
mesh_terms: D000172:Acromegaly / Q000188:drug therapy*; D000328:Adult; D000681:Amylases / Q000097:blood; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D008297:Male; D015282:Octreotide / Q000009:adverse effects*; D010195:Pancreatitis / Q000139:chemically induced*; D010456:Peptides, Cyclic / Q000009:adverse effects*; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D005765:Gastrointestinal Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D000681:Amylases; D015282:Octreotide